Treatment, tolerability and outcomes of enfortumab vedotin plus pembrolizumab in advanced urothelial carcinoma: An analysis of the Austrian enfortumab registry

This article has no abstract
Epistemonikos ID: dc989ba53cad64fd2694686e942e981237d0c6d9
First added on: Jan 22, 2026